Compare Novo Nordisk A/S (NVO) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Consumer Staples Select Sector SPDR Fund — how do they compare? Novo Nordisk A/S trades at $46.39 (market cap $207.85B), while Consumer Staples Select Sector SPDR Fund trades at $85.08. The key difference: Novo Nordisk A/S pays a 3.81% dividend while Consumer Staples Select Sector SPDR Fund pays none, and Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | XLP | |
|---|---|---|
Market Cap | $207.85B | — |
Sector | Health | — |
52-Week High | $63.98 | $90.00 |
52-Week Low | $35.29 | $75.61 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
XLP trades at $85.08 with minimal daily movement (+0.15%), reflecting stable defensive positioning. Technical indicators show mixed signals with a neutral overall rating, while analyst consensus remains strongly bullish with 100% buy ratings. The consumer staples ETF benefits from recent positive sector momentum and defensive characteristics during market uncertainty.
The outlook remains positive given the defensive nature of consumer staples amid economic uncertainty, with potential for steady dividend income. Key risks include sector rotation away from defensive plays and valuation concerns if growth expectations moderate. The 2.6% dividend yield provides income support while awaiting capital appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
